The overall goal of this competing renewal SPORE in skin Cancer from The University of Texas M.D. Anderson Cancer Center is to facilitate innovative translational research in the prevention, detection and treatment of melanoma leading to the elimination of the disease. This SPORE aims to achieve this goal by assembling a talented group of scientists who are committed to the translation of melanoma-specific findings from the laboratory to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has prioritized the elimination of melanoma as a health risk, and to this end established in 1998, a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries. The program provided resources and a structure that led to our successful funding in 2004 for the first SPORE dedicated entirely to Melanoma, which allowed us to further advance along several translational themes and provide a basis for this renewal application. This SPORE in Melanoma proposes five translational projects, four of which included treatment protocols to begin in successive years and takes advantage of our large melanoma patient population. The five projects and four protocols are served by three cores: Administrative (A), Informatics, Tissue Resource, and Pathology (B), and Biostatics and Bioinformatics (C). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as each new project incorporates at least one DRP/CDP awardee as a new Co-Leader. The five proposed projects address activation of Toll-Like Receptors (TLR) for specific immune stimulation (#1);inhibition of pSTAT3 for control of melanoma metastasis focused in the CNS (#2);elucidation of melanoma JNOS-related inflammation for development of a prognostic signature as well as a target therapy (#3);systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4);and genetic mechanisms of immunity and inflammation to generate an integrated risk model as part of a population based project (#5). Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE aims to make a significant impact toward the prevention, detection, and treatment of melanoma in patients.

Public Health Relevance

Melanoma is the most deadly form of skin cancers, and the incidence is increasing faster than any other cancer in the US at this time. The metastatic process is poorly understood, and new therapies are needed urgently. This SPORE directly addresses solving these issues through innovative translational research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Agarwal, Rajeev K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Other Domestic Higher Education
United States
Zip Code
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23:2891-2904
Kim, Dae Won; Haydu, Lauren E; Joon, Aron Y et al. (2017) Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer 123:1372-1381
Fang, Shenying; Vaysse, Amaury; Brossard, Myriam et al. (2017) Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. J Invest Dermatol 137:253-257
Rodriguez-Aguayo, Cristian; Monroig, Paloma Del C; Redis, Roxana S et al. (2017) Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029
Mbofung, Rina M; McKenzie, Jodi A; Malu, Shruti et al. (2017) HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8:451
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Li, Hong; Wang, Yanru; Liu, Hongliang et al. (2017) Genetic variants of PDGF signaling pathway genes predict cutaneous melanoma survival. Oncotarget 8:74595-74606
Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851

Showing the most recent 10 out of 271 publications